



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 213/42, C07C 311/29, A61K 31/44, 31/18		A1	(11) International Publication Number: WO 97/22587
			(43) International Publication Date: 26 June 1997 (26.06.97)
(21) International Application Number: PCT/EP96/05362		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG , SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 December 1996 (03.12.96)			
(30) Priority Data: 60/008,661 15 December 1995 (15.12.95) US			
(71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basle (CH).		Published With international search report.	
(72) Inventor; and (75) Inventor/Applicant (for US only): PARKER, David, Thomas [US/US]; 291 East Northfield Road, Livingston, NJ 07039 (US).			
(74) Common Representative: NOVARTIS AG; Patent and Trade-mark Dept., Klybeckstrasse 141, CH-4002 Basle (CH).			

(54) Title: **ALPHA-SUBSTITUTED ARYLSULPHONAMIDO HYDROXAMIC ACIDS AS TNF-ALPHA AND MATRIX METALLO-PROTEINASE INHIBITORS**

(57) Abstract

Compounds of formula (I), wherein Ar, n, R₁, R₂, R₃ and R₄ are defined in the specification, as well as pharmaceutically acceptable prodrug derivatives and pharmaceutically acceptable salts thereof, exhibit valuable pharmaceutical properties, especially as inhibitors of TNF-alpha activity and of matrix-degrading metalloproteinases. Therefore, they can be used in the treatment of a large spectrum of diseases, e.g. as antiinflammatory agents for the treatment of e.g. osteoarthritis, rheumatoid arthritis, or as antitumor agents e.g. for the treatment and prevention of tumor growth, tumor metastasis, tumor invasion or progression. They are prepared in a manner known per se.

